In a report released today, Charles Peters from Raymond James maintained a Buy rating on Healthequity (NASDAQ: HQY), with a price target of $105. The company’s shares closed on Friday at $97.07, close to its 52-week high of $97.94.
According to TipRanks.com, Peters is a 5-star analyst with an average return of 20.8% and a 80.6% success rate. Peters covers the Financial sector, focusing on stocks such as Health Insurance Innovations, Hallmark Financial Services, and Marsh & Mclennan Companies.
Currently, the analyst consensus on Healthequity is a Strong Buy with an average price target of $100.67, representing a 3.7% upside. In a report issued on August 30, Barrington also reiterated a Buy rating on the stock with a $85 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $97.94 and a one-year low of $42.92. Currently, Healthequity has an average volume of 435.1K.
Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Frank Medici, a Director at HQY sold 6,904 shares for a total of $555,013.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthEquity, Inc. engages in the provision of healthcare saving solutions. Its products include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.
